FLT3 and acute myeloid leukemia: Additionally, therapy with FLT3 inhibitors in patients with relapsed or refractory (R/R) AML who harbor FLT3-ITD mutations has been shown to promote drug-resistant clonal populations that contain secondary, on-target mutations in FLT3 that confer resistance to multiple TKIs [9, 10].